IP Library › Assignment 026609/0689
Patent Assignment
Reel/Frame 026609/0689

Assignment of Assignor's Interest

Recorded: 2011-07-18 Pages: 9
Assignor
PROTIA, LLC
Executed: 2011-07-01
Assignee
DEUTERIA PHARMACEUTICALS INCE
300 BRICKSTONE SQUARE, SUITE 201, ANDOVER, MASSACHUSETTS, 01810
Covered Properties (67)
Deuterium-Enriched Azithromycin
Application: 12/195,540 →
Publication: US 2009/0062220
Deuterium-Enriched Voriconazole
Application: 12/195,857 →
Publication: US 2009/0062310
Deuterium-Enriched Tiotropium
Application: 12/195,907 →
Publication: US 2009/0062325
Deuterium-Enriched Tolterodine
Application: 12/196,022 →
Publication: US 2009/0062398
Deuterium-Enriched Budesonide
Application: 12/196,041 →
Publication: US 2009/0082319
Deuterium-Enriched Oxybutynin
Application: 12/368,651 →
Publication: US 2009/0156671
Deuterium-Enriched Oseltamivir
Patent: 7,915,309 →
Application: 11/765,668 →
Publication: US 2008/0319064
Deuterium-Enriched Salmeterol
Application: 11/766,080 →
Publication: US 2008/0319086
Deuterium-Enriched Bupropion
Application: 12/196,231 →
Publication: US 2009/0076161
Deuterium-Enriched Capecitabine
Patent: 7,842,675 →
Application: 12/196,236 →
Publication: US 2009/0075931
Deuterium-Enriched Ciclesonide
Application: 12/196,240 →
Publication: US 2009/0075959
Deuterium-Enriched Dasatinib
Application: 12/196,336 →
Publication: US 2009/0076025
Deuterium-Enriched Donepezil
Patent: 8,304,435 →
Application: 12/196,343 →
Publication: US 2009/0069378
Deuterium-Enriched Enzastaurin
Application: 12/196,365 →
Publication: US 2009/0069377
Deuterium-Enriched Fulvestrant
Application: 12/196,380 →
Publication: US 2009/0082323
Deuterium-Enriched Ixabepilone
Application: 12/196,627 →
Publication: US 2009/0076099
Deuterium-Enriched Lenalidomide
Patent: 8,288,414 →
Application: 12/196,672 →
Publication: US 2009/0069379
Deuterium-Enriched Meropenem
Application: 12/196,773 →
Publication: US 2009/0082327
Deuterium-Enriched Octreotide
Application: 12/196,914 →
Publication: US 2009/0082259
Deuterium-Enriched Olopatadine
Application: 12/196,938 →
Publication: US 2009/0069413
Deuterium-Enriched Paclitaxel
Application: 12/196,958 →
Publication: US 2009/0069410
Deuterium-Enriched Pemetrexed
Application: 12/196,975 →
Publication: US 2009/0069349
Deuterium-Enriched Prasugrel
Patent: 8,669,268 →
Application: 12/196,989 →
Publication: US 2009/0069369
Deuterium-Enriched Raloxifene
Application: 12/197,038 →
Publication: US 2009/0069381
Deuterium-Enriched Risedronate
Application: 12/197,050 →
Publication: US 2009/0075940
Deuterium-Enriched Anidulafungin
Application: 12/198,027 →
Publication: US 2009/0062185
Deuterium-Enriched Axitinib
Application: 12/198,034 →
Publication: US 2009/0062347
Deuterium-Enriched Ruboxistaurin
Application: 12/203,331 →
Publication: US 2012/0136037
Deuterium-Enriched Prazosin
Application: 12/198,042 →
Publication: US 2009/0062300
Deuterium-Enriched Tipranavir
Application: 12/198,050 →
Publication: US 2009/0062346
Deuterium-Enriched Dalbavancin
Application: 12/198,088 →
Publication: US 2009/0062182
Deuterium-Enriched Sdx-101
Patent: 7,956,080 →
Application: 12/233,344 →
Publication: US 2009/0082417
Deuterium-Enriched Aztreonam
Application: 12/203,363 →
Publication: US 2009/0069286
Deuterium-Enriched Nebivolol
Application: 12/203,386 →
Publication: US 2009/0069415
Deuterium-Enriched Saxagliptin
Application: 12/205,590 →
Publication: US 2009/0076118
Deuterium-Enriched Lamotrigine
Application: 12/205,653 →
Publication: US 2009/0076010
Deuterium-Enriched Nelarabine
Patent: 7,846,912 →
Application: 12/205,664 →
Publication: US 2009/0075930
Deuterium-Enriched Odansetron
Patent: 7,919,516 →
Application: 12/205,677 →
Publication: US 2009/0076107
Deuterium-Enriched Retapamulin
Application: 12/205,701 →
Publication: US 2009/0076071
Deuterium-Enriched Telavancin
Application: 12/202,277 →
Publication: US 2009/0069219
Deuterium-Enriched Aliskiren
Application: 12/196,576 →
Publication: US 2009/0082458
Deuterium-Enriched Alogliptin
Application: 12/196,597 →
Publication: US 2009/0082376
Deuterium-Enriched Bazedoxifene
Application: 12/795,645 →
Publication: US 2011/0028454
Deuterium-Enriched Bendamustine
Application: 12/196,711 →
Publication: US 2009/0082416
Deuterium-Enriched Bms-690514
Application: 12/196,734 →
Publication: US 2009/0076034
Deuterium-Enriched Dapoxetine
Application: 12/196,788 →
Publication: US 2009/0076163
Deuterium-Enriched Darunavir
Application: 12/196,828 →
Publication: US 2009/0076138
Deuterium-Enriched Decitabine
Application: 12/196,853 →
Publication: US 2009/0075920
Deuterium-Enriched Doripenem
Application: 12/196,920 →
Publication: US 2009/0075969
Deuterium-Enriched Ed-71
Application: 12/196,952 →
Publication: US 2009/0075953
Deuterium-Enriched Methylphenidate
Application: 12/207,879 →
Publication: US 2009/0076079
Deuterium-Enriched Risperidone
Patent: 7,776,866 →
Application: 12/208,684 →
Publication: US 2009/0076036
Deuterium-Enriched Tafenoquine
Application: 12/206,330 →
Publication: US 2009/0076072
Deuterium-Enriched Topiramate
Application: 12/208,743 →
Publication: US 2009/0076128
Deuterium-Enriched Topotecan
Patent: 8,026,249 →
Application: 12/206,368 →
Publication: US 2009/0076056
Deuterium-Enriched Valacyclovir
Application: 12/206,396 →
Publication: US 2009/0076039
Deuterium-Enriched Valganciclovir
Application: 12/208,773 →
Publication: US 2009/0076040
Deuterium-Enriched Zanamivir
Application: 12/206,405 →
Publication: US 2009/0076133
Deuterium-Enriched Carvediolo
Application: 12/205,712 →
Publication: US 2009/0076116
Deuterium-Enriched Fexofenadine
Application: 12/210,326 →
Publication: US 2009/0076080
Deuterium-Enriched Fosaprepitant
Application: 12/535,068 →
Publication: US 2010/0029592
Deuterium-Enriched Imatinib
Application: 12/233,677 →
Publication: US 2009/0082361
Deuterium-Enriched Mometasone
Application: 12/233,725 →
Publication: US 2009/0082318
Deuterium-Enriched Pioglitazone
Patent: 8,722,710 →
Application: 12/233,751 →
Publication: US 2009/0082405
Deuterium-Enriched Posaconazole
Application: 12/234,229 →
Publication: US 2009/0082363
Deuterium-Enriched Temsirolimus
Application: 12/209,043 →
Publication: US 2009/0076060
Deuterium-Enriched Tigecycline
Application: 12/210,290 →
Publication: US 2009/0076153
Related Assignments (5)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Oct 24, 2008
From: CZARNIK, ANTHONY W
To: PROTIA, LLC
Reel/Frame 021733/0840 →
Confirmatory Assignment Aug 10, 2012
From: PROTIA, LLC
To: DEUTERIA PHARMACEUTICALS, INC.
Reel/Frame 028770/0183 →
Assignment of Assignor's Interest Jan 31, 2013
From: DEUTERIA PHARMACEUTICALS INC
To: PROTIA, LLC
Reel/Frame 029732/0858 →
Assignment of Assignor's Interest Jan 31, 2013
From: DEUTERIA PHARMACEUTICALS INC
To: DEUTERX, LLC
Reel/Frame 029731/0423 →
Assignment of Assignor's Interest Jan 20, 2026
From: DEUTERX, LLC
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 073523/0608 →